Business Description
Guardant Health Inc
NAICS : 621511
SIC : 8071
ISIN : US40131M1099
Description
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.75 | |||||
| Equity-to-Asset | -0.04 | |||||
| Debt-to-Equity | -22.29 | |||||
| Debt-to-EBITDA | -2.87 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -0.39 | |||||
| Beneish M-Score | -3.36 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 19.6 | |||||
| 3-Year EBITDA Growth Rate | -18.8 | |||||
| 3-Year EPS without NRI Growth Rate | -18.1 | |||||
| 3-Year FCF Growth Rate | -24 | |||||
| 3-Year Book Growth Rate | -53.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 18.04 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 21.3 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 77.61 | |||||
| 9-Day RSI | 73.6 | |||||
| 14-Day RSI | 68.93 | |||||
| 3-1 Month Momentum % | 75.31 | |||||
| 6-1 Month Momentum % | 10.98 | |||||
| 12-1 Month Momentum % | 56.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.22 | |||||
| Quick Ratio | 5.85 | |||||
| Cash Ratio | 5.06 | |||||
| Days Inventory | 90.68 | |||||
| Days Sales Outstanding | 47.57 | |||||
| Days Payable | 59.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.7 | |||||
| Shareholder Yield % | 0.41 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 60.32 | |||||
| Operating Margin % | -74.42 | |||||
| Net Margin % | -74.02 | |||||
| FCF Margin % | -39.73 | |||||
| ROE % | -651 | |||||
| ROA % | -30.37 | |||||
| ROIC % | -98.07 | |||||
| 3-Year ROIIC % | -297.08 | |||||
| ROC (Joel Greenblatt) % | -160.33 | |||||
| ROCE % | -34.52 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.44 | |||||
| EV-to-EBIT | -9.55 | |||||
| EV-to-Forward-EBIT | -12.55 | |||||
| EV-to-EBITDA | -10.43 | |||||
| EV-to-Forward-EBITDA | -17.23 | |||||
| EV-to-Revenue | 7.03 | |||||
| EV-to-Forward-Revenue | 5.45 | |||||
| EV-to-FCF | -17.75 | |||||
| Price-to-GF-Value | 0.94 | |||||
| Earnings Yield (Greenblatt) % | -10.47 | |||||
| FCF Yield % | -6.06 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Guardant Health Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 634.368 | ||
| EPS (TTM) (€) | -3.887 | ||
| Beta | 0.29 | ||
| 3-Year Sharpe Ratio | -0.09 | ||
| 3-Year Sortino Ratio | -0.13 | ||
| Volatility % | 95.87 | ||
| 14-Day RSI | 68.93 | ||
| 14-Day ATR (€) | 0.836238 | ||
| 20-Day SMA (€) | 32.191 | ||
| 12-1 Month Momentum % | 56.86 | ||
| 52-Week Range (€) | 14.875 - 37.08 | ||
| Shares Outstanding (Mil) | 123.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Guardant Health Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Guardant Health Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Guardant Health Inc Frequently Asked Questions
What is Guardant Health Inc(STU:5GH)'s stock price today?
The current price of STU:5GH is €36.13. The 52 week high of STU:5GH is €37.08 and 52 week low is €14.88.
When is next earnings date of Guardant Health Inc(STU:5GH)?
The next earnings date of Guardant Health Inc(STU:5GH) is 2025-02-21 Est..
Does Guardant Health Inc(STU:5GH) pay dividends? If so, how much?
Guardant Health Inc(STU:5GH) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers